We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
James Galvin, MD, MPH, FANA
Jon Toledo, MD, PhD
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Gloria Chiang, MD
Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Charles P. Vega, MD
Real World Data and the Management of Intracranial Hemorrhages (ICH) in Anticoagulated Patients
W. Brian Gibler, MD, FACEP, FACC, FAHA
Natalie Kreitzer, MD, MS
Adrian R. Parry-Jones, FRCP, PhD
David Seiffge, MD
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Case Presentation: Management of a Patient With Vitamin K Antagonist-Associated Intracranial Hemorrhage (ICH)
Repletion Management for Vitamin K Antagonist Anticoagulation
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Development of a Care Pathway Using Specific Reversal Agents for Anticoagulated Patients With ICH
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Audience Q&A
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Reverb
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education